Taken together, and until now, the results of mTOR inhibition therapy in ADPKD in humans, contrary to the impression left by animal model studies, does not consistently confirm the beneficial impact on renal volume or function. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.